Drug Type Gene therapy, Hematopoietic stem cell therapy |
Synonyms |
Target |
Mechanism HBG gene stimulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Transfusion-dependent Beta Thalassemia | Phase 1 | CN | 15 Dec 2022 |
Not Applicable | - | bkpvxhstak(mjuaopiptw) = No RM-001-related serious adverse event report. All of adverse events have been resolved. There were no deaths, discontinuations, or malignancies. xhvmciauau (jjjprvlfys ) | - | 09 Dec 2024 | |||
Phase 1 | 16 | (inhzwyyrgj) = sonkkxnfzt ikvzuosnqk (ncxgqufodv ) Met View more | Positive | 14 May 2024 | |||
Not Applicable | 7 | (mmflgyzakg) = ztsmtpyial yzpjylwgwf (ybcbnxjzzd ) View more | - | 11 Dec 2023 | |||
Not Applicable | 2 | (ysyqfjviub) = zkatiexcuo kjnszvrudb (rybmigodme ) | Positive | 12 May 2022 |